AstraZeneca (AZN) Given Hold Rating at Jefferies Financial Group

Jefferies Financial Group restated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday. Jefferies Financial Group currently has a GBX 5,800 ($75.79) price objective on the biopharmaceutical company’s stock.

Several other brokerages have also commented on AZN. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 18th. Kepler Capital Markets raised their price objective on shares of AstraZeneca from GBX 5,630 ($73.57) to GBX 6,100 ($79.71) and gave the stock a buy rating in a report on Friday, September 7th. Deutsche Bank restated a buy rating and issued a GBX 6,000 ($78.40) price objective on shares of AstraZeneca in a report on Friday, July 27th. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Thursday, August 30th. Finally, UBS Group set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca and gave the stock a neutral rating in a report on Monday, June 25th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. AstraZeneca has a consensus rating of Hold and an average target price of GBX 5,700.70 ($74.49).

AZN traded down GBX 70 ($0.91) on Friday, hitting GBX 5,546 ($72.47). The company had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Why do companies issue stock splits?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply